Vaccine composition for use against influenza
US-9220767-B2 · Dec 29, 2015 · US
US9801927B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9801927-B2 |
| Application number | US-201113636482-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 29, 2011 |
| Priority date | Mar 29, 2010 |
| Publication date | Oct 31, 2017 |
| Grant date | Oct 31, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to pharmaceutical compositions using a polypeptide comprising at least one CXXC motif, such as Giardia parasite's variable surface proteins (VSP) or a fragment thereof to raise by oral or mucosal vaccination an immune response against a heterologous selected antigen, such as tumor antigen, microbial antigen or other antigen.
Opening claim text (preview).
The invention claimed is: 1. An immunogenic composition against an antigen comprising: an antigen bound to a polypeptide, wherein the polypeptide: is heterologous to the antigen, comprises 10 to 14 CXXC motifs, wherein C represents a cysteine residue and X any amino acid residue, is a variable surface protein (VSP), a VSP-like protein of a microorganism or a fragment thereof, and is able to attach to epithelial cells of the gut, and wherein CXXC corresponds to SEQ ID NO 1, wherein the microorganism is selected from the group consisting of Giardia, Tetrahymena, Paramecium and Entamoeba species, wherein the polypeptide is bound to a vector particle containing said antigen, and wherein the vector particle is a viral particle, a viral-like particle (VLP) or a nanoparticle. 2. The immunogenic composition according to claim 1 for use in oral administration. 3. The immunogenic composition according to claim 1 , wherein the polypeptide is resistant to enzymatic and/or chemical degradation of the upper gastrointestinal tract. 4. The immunogenic composition according to claim 1 , wherein the polypeptide is the extracellular domain of VSP or a fragment thereof. 5. The immunogenic composition according to claim 1 , wherein the polypeptide is fused to said antigen. 6. The immunogenic composition according to claim 1 , wherein The polypeptide is bound to a vector particle containing said antigen, and wherein the vector particle is a VLP displaying at its surface the polypeptide. 7. The immunogenic composition according to claim 6 , wherein the antigen is contained inside or on the surface of the VLP. 8. The immunogenic composition according to claim 1 , wherein the vector particle is a nanoparticle displaying at its surface the polypeptide and the heterologous antigen. 9. A pharmaceutical composition comprising at least the vaccine according to claim 1 . 10. A method of immunization of a subject against an influenza A H5N1, wherein said method comprises administering to said subject said antigen bound to a polypeptide, wherein the polypeptide: is heterologous to said antigen, comprises 10 to 14 CXXC motifs, wherein C represents a cysteine residue and X any amino acid residue, is a variable surface protein (VSP), a VSP-like protein of a microorganism or a fragment thereof, and is able to attach to epithelial cells of the gut, and wherein CXXC corresponds to SEQ ID NO 1, wherein the microorganism is selected from the group consisting of Giardia, Tetrahymena, Paramecium and Entamoeba species, wherein the polypeptide is bound to a vector particle containing said antigen, and wherein the vector particle is a viral particle, a viral-like particle (VLP) or a nanoparticle. 11. The method of claim 10 , wherein said antigen bound to a polypeptide is administered by oral route.
Related publications grouped by family.
Answers are generated from the same data shown on this page.